{"id":37209,"date":"2021-09-29T00:53:39","date_gmt":"2021-09-28T16:53:39","guid":{"rendered":"https:\/\/case.ntu.edu.tw\/blog\/?p=37209"},"modified":"2021-09-14T12:55:33","modified_gmt":"2021-09-14T04:55:33","slug":"%e4%bb%80%e9%ba%bc%e6%98%af%e3%80%8c%e5%85%8d%e7%96%ab%e6%a9%8b%e6%8e%a5%e3%80%8d%ef%bc%9f%e6%a0%b9%e6%93%9a%e5%85%8d%e7%96%ab%e6%a9%8b%e6%8e%a5%e6%95%b8%e6%93%9a%e5%8f%af%e4%bb%a5%e9%a0%90%e6%b8%ac","status":"publish","type":"post","link":"https:\/\/case.ntu.edu.tw\/blog\/?p=37209","title":{"rendered":"\u4ec0\u9ebc\u662f\u300c\u514d\u75ab\u6a4b\u63a5\u300d\uff1f\u6839\u64da\u514d\u75ab\u6a4b\u63a5\u6578\u64da\u53ef\u4ee5\u9810\u6e2c\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\u679c\u55ce\uff1f"},"content":{"rendered":"

\u5b8c\u6210\u85e5\u7269\u958b\u767c\u7684\u5168\u90e8\u81e8\u5e8a\u4e09\u671f\u8a66\u9a57\u9808\u8017\u8cbb\u5927\u91cf\u4eba\u529b\u3001\u7269\u8cc7\u53ca\u7d93\u8cbb\uff0c\u9084\u9700\u8981\u5927\u91cf\u5fd7\u9858\u53d7\u8a66\u8005\u53c3\u8207\u8a66\u9a57\uff0c\u5f80\u5f80\u9700\u6642\u751a\u4e45\u3002\u5728\u7f3a\u4e4f\u5b8c\u6574\u81e8\u5e8a\u8a66\u9a57\u53ca\u4fdd\u8b77\u529b\u6578\u64da\u7684\u60c5\u6cc1\u4e0b\uff0c\u514d\u75ab\u6a4b\u63a5\uff08immunobridging\uff09\u662f\u4e00\u7a2e\u80fd\u5920\u5206\u6790\u53ca\u63a8\u65b7\u75ab\u82d7\u4fdd\u8b77\u4f5c\u7528\u7684\u65b9\u6cd5\uff0c\u900f\u904e\u5c07\u75ab\u82d7\u7684\u514d\u75ab\u539f\u6027\u8f49\u5316\u70ba\u4fdd\u8b77\u4f5c\u7528\uff0c\u53ef\u4ee5\u5f97\u77e5\u514d\u75ab\u539f\u6027\u8207\u5728\u9069\u5408\u52d5\u7269\u6a21\u578b\u4e2d\u8a66\u9a57\u7d50\u679c\u4e4b\u9593\u7684\u95dc\u4fc2\u3002\u5728\u672c\u6587\uff0c\u6211\u5011\u5c07\u5f15\u9818\u8b80\u8005\u8a8d\u8b58\u514d\u75ab\u6a4b\u63a5\u53ca\u5982\u4f55\u85c9\u4ee5\u63a8\u6e2c\u75ab\u82d7\u4fdd\u8b77\u529b\uff0c\u4e26\u63a2\u7d22\u6839\u64da\u514d\u75ab\u6a4b\u63a5\u6578\u64da\u662f\u5426\u8db3\u4ee5\u9810\u6e2c\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\u679c\u3002<\/strong><\/span><\/p>\n

\"\"
\u5716\u7247\u4f86\u6e90\uff1aPixabay<\/figcaption><\/figure>\n

\u64b0\u6587\uff5c\u9673\u6df5\u9293<\/strong><\/p>\n

\u25cf\u8a8d\u8b58\u514d\u75ab\u6a4b\u63a5<\/strong><\/span><\/p>\n

\u5047\u5982\u7814\u767c\u4eba\u54e1\u767c\u73fe\u8981\u5728\u5b8c\u6574\u7684\u81e8\u5e8a\u8a66\u9a57\uff08\u7b2c\u4e00\u3001\u4e8c\u3001\u4e09\u671f\u8a66\u9a57\uff09\u8b49\u660e\u75ab\u82d7\u529f\u6548\u5728\u6280\u8853\u6216\u502b\u7406\u4e0a\u662f\u4e0d\u53ef\u884c\u6642\uff0c\u4fbf\u53ef\u8a55\u4f30\u63a1\u7528\u5176\u4ed6\u65b9\u6cd5\u8b49\u660e\u75ab\u82d7\u7684\u81e8\u5e8a\u6548\u76ca\uff0c\u53ef\u80fd\u7684\u6307\u5357\u5305\u62ec\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\uff08FDA\uff09\u7684\u52d5\u7269\u898f\u5247\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40\u5728\u7279\u6b8a\u60c5\u6cc1\u4e0b\u7684\u6709\u689d\u4ef6\u6279\u51c6\u53ca\u52a0\u62ff\u5927\u885b\u751f\u90e8\u5c0d\u65b0\u85e5\u7684\u7279\u6b8a\u4f7f\u7528\u898f\u5b9a\u7b49\u3002\u9019\u4e9b\u6307\u5357\u898f\u5b9a\u5728\u5408\u9069\u7684\u52d5\u7269\u6a21\u578b\u4e2d\uff0c\u8207\u4fdd\u8b77\u76f8\u95dc\u7684\u514d\u75ab\u6a19\u8a8c\u7269\u53ef\u7528\u65bc\u8b49\u660e\u81e8\u5e8a\u7372\u76ca\u7684\u53ef\u80fd\u6027\u3001\u4f5c\u70ba\u8a31\u53ef\u7684\u57fa\u790e\u53ca\u984d\u5916\u7684\u8a31\u53ef\u5f8c\u627f\u8afe\uff0c\u4f8b\u5982\uff1a\u7528\u65bc\u9810\u9632\u70ad\u75bd\u82bd\u5b62\u687f\u83cc\uff08Bacillus anthracis<\/em>\uff09\u5f15\u767c\u75be\u75c5\u7684\u75ab\u82d7BioThrax\u00ae<\/sup>\u57282018\u5e74\u6210\u70ba\u7b2c\u4e00\u500b\u6839\u64da\u7f8e\u570bFDA\u52d5\u7269\u898f\u5247\u7372\u5f97\u8a31\u53ef\u7684\u75ab\u82d7\u3002<\/p>\n

\u6211\u570b\u885b\u751f\u798f\u5229\u90e8\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u7f72\u4ee5\u300c\u514d\u75ab\u6a4b\u63a5\uff08immunobridging\uff09\u300d\u65b9\u5f0f\uff0c\u63a1\u7528\u300c\u4e2d\u548c\u6297\u9ad4\u6548\u50f9\uff08neutralizing antibody titer\uff09\u300d\u4f5c\u70ba\u66ff\u4ee3\u6027\u7642\u6548\u6307\u6a19\uff0c\u8861\u91cf\u570b\u7522\u65b0\u51a0\u80ba\u708e\uff08COVID-19\uff09\u75ab\u82d7\u6240\u8a98\u767c\u7684\u514d\u75ab\u539f\u6027\uff08immunogenicity\uff09\u7d50\u679c\uff0c\u662f\u5426\u53ef\u8207\u570b\u5916\u5df2\u6838\u51c6\u7684\u7dca\u6025\u4f7f\u7528\u6388\u6b0a\uff08EUA\uff09\u7684\u75ab\u82d7\u76f8\u7576\u3002\u76ee\u524d\u5df2\u5728\u53f0\u7063\u7372\u5f97EUA\u958b\u59cb\u5927\u898f\u6a21\u63a5\u7a2e\u7684\u9ad8\u7aef\u75ab\u82d7\uff08MVC COVID-19 vaccine\uff09\u5c31\u662f\u63a1\u7528\u514d\u75ab\u6a4b\u63a5\u7684\u6280\u8853\uff0c\u4ee5AZ\u75ab\u82d7\u4e2d\u7684\u4e2d\u548c\u6297\u9ad4\u505a\u70ba\u66ff\u4ee3\u7642\u6548\u6307\u6a19\uff0c\u662f\u5168\u7403\u9996\u6b3e\u4ee5\u300c\u514d\u75ab\u6a4b\u63a5\u300d\u6280\u8853\u7814\u767c\u6295\u5165\u7dca\u6025\u4f7f\u7528\u7684 COVID-19\u75ab\u82d7\u3002\u96d6\u7136\u514d\u75ab\u6a4b\u63a5\u5047\u8a2d\u4fdd\u8b77\u6a5f\u5236\u5728\u52d5\u7269\u6a21\u5f0f\u548c\u4eba\u985e\u4e4b\u9593\u662f\u4fdd\u5b88\u4e14\u76f8\u7576\u7684\uff0c\u4f46\u9078\u64c7\u7528\u65bc\u514d\u75ab\u6a4b\u63a5\u7684\u514d\u75ab\u6a19\u8a18\u53ea\u9700\u8981\u8207\u6240\u9700\u7684\u81e8\u5e8a\u6548\u76ca\u76f8\u95dc\u806f\uff0c\u4e26\u4e0d\u4e00\u5b9a\u53c3\u8207\u4fdd\u8b77\u6a5f\u5236\u3002<\/p>\n

\u25cf\u91dd\u5c0d\u4e2d\u548c\u6297\u9ad4\u6c34\u5e73\u7684\u75ab\u82d7\u4fdd\u8b77\u529b\u5206\u6790<\/strong><\/span><\/p>\n

\u57282021\u5e74\uff0c\u6fb3\u6d32\u79d1\u5b78\u5bb6David S. Khoury\u7b49\u5728\u570b\u969b\u671f\u520a\u300aNature Medicine\u300b\u767c\u8868\u8a55\u8ad6\u6587\u7ae0\uff0c\u7814\u7a76\u5728\u570b\u969b\u4e0a\u5df2\u7372EUA\u7684\u75ab\u82d7\u4fdd\u8b77\u529b\u4e4b\u76f8\u95dc\u5b78\u8853\u6587\u737b\uff0c\u6839\u64daCOVID-19\u7684\u514d\u75ab\u4fdd\u8b77\u9810\u6e2c\u6a21\u578b\u4f86\u78ba\u5b9a\u4fdd\u8b77\u529b\u7684\u76f8\u95dc\u6027\uff0c\u7528\u4ee5\u5354\u52a9\u672a\u4f86\u7684\u75ab\u82d7\u90e8\u7f72\u3002<\/p>\n

\u4ed6\u5011\u4f7f\u7528\u4f86\u81ea\u4e03\u7a2eCOVID-19\u75ab\u82d7\uff08Moderna, Pfizer\/BNT, AstraZeneca, Johnson & Johnson, Sinovac, Sputnik V, Bharat Biotech\uff09\u548c\u6062\u5fa9\u671f\u968a\u5217\uff08convalescent cohort\uff09\u7684\u6578\u64da\uff0c\u5206\u6790\u6d3b\u9ad4\u5916\u4e2d\u548c\u6297\u9ad4\u6c34\u5e73\uff08level\uff09\uff0c\u4e26\u89c0\u5bdf\u5c0dSARS-CoV-2\u75c5\u6bd2\u611f\u67d3\u4fdd\u8b77\u529b\uff08protective efficacy\uff09\u4e4b\u9593\u7684\u95dc\u4fc2\u3002\u6578\u64da\u986f\u793a\u91dd\u5c0dSARS-CoV-2 \u611f\u67d3\u63d0\u4f9b50% \u4fdd\u8b77\u529b\u7684\u4e2d\u548c\u6297\u9ad4\u6c34\u5e73\u70ba\u5e73\u5747\u6062\u5fa9\u671f\u6c34\u5e73\u7684 20.2%\uff0895% \u4fe1\u8cf4\u5340\u9593 (CI) : 14.4\u201328.4%\uff09\uff1b\u5c0d\u56b4\u91cd\u611f\u67d3\u63d0\u4f9b50%\u4fdd\u8b77\u529b\u6240\u9700\u7684\u4f30\u8a08\u4e2d\u548c\u6297\u9ad4\u6c34\u5e73\u660e\u986f\u8f03\u4f4e\uff08\u5e73\u5747\u6062\u5fa9\u671f\u6c34\u5e73\u7684 3%\uff1b95% CI: 0.7-13%\uff0cP= 0.0004\uff09\uff0c\u800c\u4e14\u4e2d\u548c\u6297\u9ad4\u7684\u6548\u50f9\u5728250\u5929\u5f8c\u6703\u8870\u9000\u6216\u6e1b\u5f31\u3002\u7814\u7a76\u7d50\u679c\u8868\u660e\uff0c\u96d6\u7136\u75ab\u82d7\u5c55\u73fe\u5f88\u5927\u7a0b\u5ea6\u4fdd\u7559\u5c0d\u91cd\u75c7\u7684\u4fdd\u8b77\u529b\uff0c\u4f46\u5c0dSARS-CoV-2 \u611f\u67d3\u7684\u4fdd\u8b77\u4f5c\u7528\u986f\u8457\u55aa\u5931\u3002<\/p>\n

\u6b64\u5916\uff0c\u91dd\u5c0d\u67d0\u4e9b SARS-CoV-2\u8b8a\u7570\u682a\u7684\u4e2d\u548c\u6297\u9ad4\u6548\u50f9\u964d\u4f4e\uff0c\u6a21\u578b\u9810\u6e2c\u4e2d\u548c\u4f5c\u7528\u8207\u5c0d\u75c5\u6bd2\u8b8a\u7570\u682a\u7684\u4fdd\u8b77\u529b\u9593\u7684\u95dc\u4fc2\uff0c\u5c55\u73fe\u4e86\u4e2d\u548c\u6297\u9ad4\u6c34\u5e73\u5c0d\u514d\u75ab\u4fdd\u8b77\u7684\u9ad8\u5ea6\u9810\u6e2c\uff0c\u4e26\u63d0\u4f9b\u4e86\u75ab\u82d7\u5c0dSARS-CoV-2 \u4fdd\u8b77\u529b\u7684\u9a57\u8b49\u6a21\u578b\uff0c\u6709\u52a9\u65bc\u5236\u5b9a\u75ab\u82d7\u7b56\u7565\u4ee5\u63a7\u5236COVID-19\u7684\u5927\u6d41\u884c\u3002<\/p>\n

\u7136\u800c\uff0c\u9019\u4e9b\u7814\u7a76\u4eba\u54e1\u6240\u505a\u7684\u300c\u514d\u75ab\u6a4b\u63a5\u5206\u6790\u300d\u662f\u7528\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u6578\u64da\u4f86\u652f\u6301\u7684\uff0c\u7528\u4f86\u5206\u6790\u95dc\u806f\u6027\u7684\u4fdd\u8b77\u529b\u6578\u64da\uff0c\u61c9\u900f\u904e\u5be6\u969b\u7684\u81e8\u5e8a\u8a66\u9a57\u6578\u64da\u53bb\u89c0\u5bdf\u53d7\u8a66\u8005\u5f9e\u91cd\u75c7\u6062\u5fa9\u5230\u8f15\u75c7\uff0c\u6216\u662f\u5f9e\u81f4\u6b7b\u5a01\u8105\u4e2d\u812b\u96e2\u7684\u904e\u7a0b\uff0c\u5982\u679c\u53ea\u770b\u5065\u5eb7\u7684\u4eba\u5728\u63a5\u7a2e\u75ab\u82d7\u5f8c\u7684\u8cc7\u6599\uff0c\u9019\u6a23\u7684\u8840\u6e05\u5b78\u6578\u64da\u5f88\u96e3\u4ee3\u8868\u5b8c\u6574\u7684\u4fdd\u8b77\u529b\u3002<\/p>\n

\u25cf\u514d\u75ab\u6a4b\u63a5\u7528\u65bc\u75ab\u82d7\u7814\u767c\u7684\u76f8\u95dc\u7814\u7a76<\/strong><\/span><\/p>\n

\u57282020 \u5e74\uff0c\u591a\u570b\u7814\u7a76\u4eba\u54e1\u5408\u4f5c\u5728\u5766\u6851\u5c3c\u4e9e\u9032\u884c\u4e00\u9805\u6e1b\u5c11\u4eba\u985e\u4e73\u7a81\u75c5\u6bd2\uff08Human papillomavirus<\/em>, HPV\uff09\u75ab\u82d7\u5291\u91cf\u8a08\u5283\u7684\u96a8\u6a5f\u5c0d\u7167\u8a66\u9a57\uff0c\u4ee5\u78ba\u5b9a\u55ae\u6b21\u63a5\u7a2e\u662f\u5426\u6703\u7522\u751f\u6709\u6548\u9810\u9632\u5b50\u5bae\u9838\u764c\u7684\u514d\u75ab\u53cd\u61c9\u3002\u5171\u6709930 \u540d 9-14 \u6b72\u5973\u5b69\u88ab\u96a8\u6a5f\u5206\u914d\u5230 6\u7d44\uff0c\u5305\u62ec3\u7a2e\u4e0d\u540c\u5291\u91cf\u7684 2 \u50f9 (Cervarix) \u548c9\u50f9 (Gardasil-9) HPV \u75ab\u82d7\uff1a3 \u5291\u30012 \u5291\uff08\u9593\u9694 6 \u500b\u6708\uff09\u6216\u55ae\u5291\u91cf\u3002\u8a66\u9a57\u7d50\u679c\u8457\u91cd\u65bc\u75ab\u82d7\u514d\u75ab\u53cd\u61c9\uff0c\u5305\u62ecHPV 16\/18\u7279\u7570\u6027\u6297\u9ad4\u6c34\u5e73\u3001\u6297\u9ad4\u89aa\u548c\u529b\u548c\u8a18\u61b6 B \u7d30\u80de\u53cd\u61c9\u3002\u8a66\u9a57\u7d50\u679c\u5c07\u88ab\u514d\u75ab\u6a4b\u63a5\u81f3\u5df2\u8b49\u660e\u7642\u6548\u7684\u6b77\u53f2\u968a\u5217\uff08historical cohorts\uff09\u7684\u5973\u5b69\u548c\u5e74\u8f15\u5973\u6027\u3002<\/p>\n

\u9019\u662f\u91dd\u5c0d\u76ee\u6a19\u5e74\u9f61\u7d44\u7684\u55ae\u5291HPV\u75ab\u82d7\u8a08\u5283\u7684\u7b2c\u4e00\u500b\u96a8\u6a5f\u8a66\u9a57\uff0c\u5c07\u53ef\u7528\u65bc\u6aa2\u67e5\u5728\u7627\u75be\u548c\u5176\u4ed6\u53ef\u80fd\u5f71\u97ff\u514d\u75ab\u53cd\u61c9\u7684\u9ad8\u8ca0\u64d4\u4eba\u7fa4\u4e2d\u6e1b\u5c11\u75ab\u82d7\u5291\u91cf\u7684\u514d\u75ab\u53cd\u61c9\u7684\u54c1\u8cea\u548c\u6301\u4e45\u6027\u3002<\/p>\n

\u5168\u7403\u79d1\u5b78\u5bb6\u5df2\u666e\u904d\u8a8d\u70ba\u5c0d\u4f0a\u6ce2\u62c9\u75c5\u6bd2 (Ebola virus, EBOV ) \u75ab\u82d7\u9032\u884c\u5927\u898f\u6a21\u7684\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u529f\u6548\u6e2c\u8a66\u5177\u6709\u6975\u9ad8\u6311\u6230\u6027\u3002\u56e0\u6b64\uff0c\u5fb7\u570b\u53ca\u6bd4\u5229\u6642\u7814\u7a76\u4eba\u54e1\u57282020 \u5e74\u5efa\u8b70\u4f7f\u7528\u514d\u75ab\u6a4b\u63a5\u63a8\u6e2c Ad26.ZEBOV\u3001MVA-BN-Filo \u75ab\u82d7\u65b9\u6848\u5728\u4eba\u985e\u7684\u4fdd\u8b77\u4f5c\u7528\u3002\u4ed6\u5011\u4f7f\u7528\u5177\u5b8c\u5168\u81f4\u6b7b\u80fd\u529b\u7684\u4f0a\u6ce2\u62c9\u75c5\u6bd2Kikwit\u653b\u64ca\u6a21\u578b\uff08challenge model\uff09\uff0c\u5728\u9748\u9577\u985e\u52d5\u7269\uff0d\u98df\u87f9\u7334\u4e2d\u7372\u5f97Ad26.ZEBOV\u548cMVA-BN Filo\u75ab\u82d7\u65b9\u6848\u7684\u514d\u75ab\u539f\u6027\u548c\u4fdd\u8b77\u529b\u6578\u64da\u3002\u4ed6\u5011\u7814\u7a76\u91dd\u5c0d\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u7684\u4e2d\u548c\u6297\u9ad4\u3001\u91a3\u86cb\u767d\u7d50\u5408\u6297\u9ad4\u53ca\u91a3\u86cb\u767d\u53cd\u61c9\u6027T\u7d30\u80de\u8207\u98df\u87f9\u7334\u5b58\u6d3b\u7387\u4e4b\u9593\u7684\u95dc\u806f\u6027\uff0c\u518d\u4f7f\u7528\u908f\u8f2f\u56de\u6b78\u5206\u6790\uff08logistic regression analysis\uff09\u9032\u884c\u8a55\u4f30\u3002<\/p>\n

\u7d50\u679c\u767c\u73fe\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u8868\u9762\u91a3\u86cb\u767d\u7684\u7d50\u5408\u6297\u9ad4\u662f\u8207\u75c5\u6bd2\u653b\u64ca\u5f8c\u5b58\u6d3b\u7387\u76f8\u95dc\u6027\u6700\u5f37\u7684\u6297\u9ad4\uff0c\u53e6\u4f7f\u7528\u7b2c\u4e00\u671f\u81e8\u5e8a\u8a66\u9a57\u5df2\u767c\u8868\u7684\u6578\u64da\u4f86\u9810\u6e2c\u75ab\u82d7\u5c0d\u4eba\u985e\u7684\u4fdd\u8b77\u4f5c\u7528\uff0c\u986f\u793a\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u75ab\u82d7\u5f15\u767c\u7684\u91a3\u86cb\u767d\u7d50\u5408\u6297\u9ad4\u53ef\u4ee5\u986f\u8457\u4fdd\u8b77\u98df\u87f9\u7334\u514d\u53d7\u75c5\u6bd2\u611f\u67d3\u800c\u6b7b\u4ea1\u3002\u4ed6\u5011\u8a8d\u70ba\u6839\u64da\u514d\u75ab\u6a4b\u63a5\u7684\u5206\u6790\uff0c\u53ef\u4ee5\u63a8\u8ad6 Ad26.ZEBOV\u3001MVA-BN-Filo \u75ab\u82d7\u65b9\u6848\u5f15\u767c\u7684\u7279\u7570\u6027\u91a3\u86cb\u767d\u7d50\u5408\u6297\u9ad4\u6c34\u5e73\uff0c\u61c9\u53ef\u63d0\u4f9b\u4eba\u985e\u8db3\u5920\u4fdd\u8b77\u529b\u4ee5\u514d\u53d7\u5230\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u5f15\u8d77\u75be\u75c5\u7684\u4fb5\u8972\u3002<\/p>\n

 <\/strong><\/p>\n

\u53c3\u8003\u8cc7\u6599<\/strong><\/p>\n

    \n
  1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038\/s41591-021-01377-8. Epub 2021 May 17.<\/li>\n
  2. Baisley KJ, Whitworth HS, Changalucha J, Pinto L, Dillner J, Kapiga S, de Sanjos\u00e9 S, Mayaud P, Hayes RJ, Lacey CJ, Watson-Jones D. A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial. Contemp Clin Trials. 2021 Feb; 101:106266. doi: 10.1016\/j.cct.2021.106266. Epub 2021 Jan 6.<\/li>\n
  3. Roozendaal R, Hendriks J, van Effelterre T, Spiessens B, Dekking L, Solforosi L, Czapska-Casey D, Bockstal V, Stoop J, Splinter D, Janssen S, Baelen BV, Verbruggen N, Serroyen J, Dekeyster E, Volkmann A, Wollmann Y, Carrion R Jr, Giavedoni LD, Robinson C, Leyssen M, Douoguih M, Luhn K, Pau MG, Sadoff J, Vandebosch A, Schuitemaker H, Zahn R, Callendret B. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. NPJ Vaccines. 2020 Dec 17;5(1):112. doi: 10.1038\/s41541-020-00261-9.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    \u5b8c\u6210\u85e5\u7269\u958b\u767c\u7684\u5168\u90e8\u81e8\u5e8a\u4e09\u671f\u8a66\u9a57\u9808\u8017\u8cbb\u5927\u91cf\u4eba\u529b\u3001\u7269\u8cc7\u53ca\u7d93\u8cbb\uff0c\u9084\u9700\u8981\u5927\u91cf\u5fd7\u9858\u53d7\u8a66\u8005\u53c3\u8207\u8a66\u9a57\uff0c\u5f80\u5f80\u9700\u6642\u751a\u4e45\u3002\u5728\u7f3a\u4e4f\u5b8c\u6574\u81e8\u5e8a\u8a66\u9a57\u53ca\u4fdd\u8b77\u529b\u6578\u64da\u7684\u60c5\u6cc1\u4e0b\uff0c\u514d\u75ab\u6a4b\u63a5\uff08immunobridging\uff09\u662f\u4e00\u7a2e\u80fd\u5920\u5206\u6790\u53ca\u63a8\u65b7\u75ab\u82d7\u4fdd\u8b77\u4f5c\u7528\u7684\u65b9\u6cd5\uff0c\u900f\u904e\u5c07\u75ab\u82d7\u7684\u514d\u75ab\u539f\u6027\u8f49\u5316\u70ba\u4fdd\u8b77\u4f5c\u7528\uff0c\u53ef\u4ee5\u5f97\u77e5\u514d\u75ab\u539f\u6027\u8207\u5728\u9069\u5408\u52d5\u7269\u6a21\u578b\u4e2d\u8a66\u9a57\u7d50\u679c\u4e4b\u9593\u7684\u95dc\u4fc2\u3002\u5728\u672c\u6587\uff0c\u6211\u5011\u5c07\u5f15\u9818\u8b80\u8005\u8a8d\u8b58\u514d\u75ab\u6a4b\u63a5\u53ca\u5982\u4f55\u85c9\u4ee5\u63a8\u6e2c\u75ab\u82d7\u4fdd\u8b77\u529b\uff0c\u4e26\u63a2\u7d22\u6839\u64da\u514d\u75ab\u6a4b\u63a5\u6578\u64da\u662f\u5426\u8db3\u4ee5\u9810\u6e2c\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\u679c\u3002<\/p>\n","protected":false},"author":20,"featured_media":37213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4580,3293,1025],"tags":[5054,5057,5058,5056,5055],"aioseo_notices":[],"jetpack_featured_media_url":"https:\/\/case.ntu.edu.tw\/blog\/wp-content\/uploads\/2021\/09\/64643614.jpg","_links":{"self":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/37209"}],"collection":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37209"}],"version-history":[{"count":1,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/37209\/revisions"}],"predecessor-version":[{"id":37214,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/posts\/37209\/revisions\/37214"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=\/wp\/v2\/media\/37213"}],"wp:attachment":[{"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/case.ntu.edu.tw\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}